MedTrace Logo

ACCLAIM - Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy

NCT00111969 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2016

Last updated 2006-07-04

No results posted yet for this study

Summary

The purpose of this study is to test the safety and efficacy of the Celacade™ system in reducing the risk of mortality and cardiovascular hospitalizations in patients with chronic systolic heart failure.

Conditions

  • Heart Failure, Congestive

Interventions

DEVICE

Celacade™ system

Sponsors & Collaborators

  • Vasogen

    lead INDUSTRY

Principal Investigators

  • Andrea B Parker, PhD · Vasogen Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Completion
2005-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00111969 on ClinicalTrials.gov